New weekly injection shows promise for boosting growth in kids with dwarfism

NCT ID NCT05598320

Completed Disease control Sponsor: Ascendis Pharma Growth Disorders A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tested a once-weekly injection called TransCon CNP in 84 children aged 2 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it safely increases growth rate over a year compared to a placebo. After the first year, all children could receive the drug in an open-label extension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

achondroplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACHONDROPLASIA

Contacts and locations

Locations

Ascendis Pharma Investigational Site

Saint Paul, Minnesota, 55102, United States
Ascendis Pharma Investigational Site

Columbia, Missouri, 65212, United States
Ascendis Pharma Investigational Site

Houston, Texas, 77030, United States
Ascendis Pharma Investigational Site

Madison, Wisconsin, 53705, United States
Ascendis Pharma Investigational Site

Parkville, 3052, Australia
Ascendis Pharma Investigational Site

Montreal, H3T 1CS, Canada
Ascendis Pharma Investigational Site

Copenhagen, 2100, Denmark
Ascendis Pharma Investigational Site

Dublin, D01 YC76, Ireland
Ascendis Pharma Investigational Site

Auckland, 1023, New Zealand
Ascendis Pharma Investigational Site

Vitoria-Gasteiz, 1008, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.